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Abstract
Background: Molecular apoptosis imaging is frequently discussed to be useful for monitoring cancer therapy. We
demonstrate that the sole assessment of therapy effects by apoptosis imaging can be misleading, depending on
the therapy effect on the tumor vasculature.
Methods: Apoptosis was investigated by determining the uptake of Annexin Vivo by optical imaging (study part I)
and of 99 mTc-6-hydrazinonicotinic [HYNIC]-radiolabeled Annexin V by gamma counting (study part II) in
subcutaneous epidermoid carcinoma xenografts (A431) in nude mice after antiangiogenic treatment (SU11248).
Optical imaging was performed by optical tomography (3D) and 2D reflectance imaging (control, n = 7; therapy, n
= 6). Accumulation of the radioactive tracer was determined ex vivo (control, n = 5; therapy, n = 6). Tumor
vascularization was investigated with an optical blood pool marker (study part I) and contrast-enhanced ultrasound
(both studies). Data were validated by immunohistology.
Results: A significantly higher apoptosis rate was detected in treated tumors by immunohistological terminal
deoxynucleotidyl transferase-mediated dUTP nick end labeling staining (area fraction: control, 0.023 ± 0.015%;
therapy, 0.387 ± 0.105%; P < 0.001). However, both 2D reflectance imaging using Annexin Vivo (control, 13 ± 15 FI/
cm2; therapy, 11 ± 7 FI/cm2) and gamma counting using 99 mTc-HYNIC-Annexin V (tumor-to-muscle ratio control,
5.66 ± 1.46; therapy, 6.09 ± 1.40) failed in showing higher accumulation in treated tumors. Optical tomography
even indicated higher probe accumulation in controls (control, 81.3 ± 73.7 pmol/cm3; therapy, 27.5 ± 34.7 pmol/
cm3). Vascularization was strongly reduced after therapy, demonstrated by contrast-enhanced ultrasound, optical
imaging, and immunohistology.
Conclusions: The failure of annexin-based apoptosis assessment in vivo can be explained by the significant
breakdown of the vasculature after therapy, resulting in reduced probe/tracer delivery. This favors annexin-based
apoptosis imaging only in therapies that do not severely interfere with the vasculature.
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Background
Apoptosis has important functions for tissue homeos-
tasis and is dysregulated in a variety of diseases [1,2].
Whereas apoptosis is increased in cardiovascular and
neurodegenerative disorders, insufficient apoptosis
occurs in autoimmune diseases, and the pronounced
loss of apoptosis is a hallmark of cancer tissue [1,2].
On the other hand, efficient cancer therapies like
chemotherapy, radiation, or antiangiogenic treatment
induce apoptosis in the tumor tissue. Thus, the detec-
tion of apoptosis, especially by noninvasive imaging
technologies, is potentially of great interest for disease
diagnosis, monitoring of the disease course, as well as
treatment response. One characteristic event in apop-
tosis is the externalization of phosphatidylserines [PS]
at the plasma membrane. The binding of the multi-
function protein Annexin V to PS has been used for
diagnostic purposes [2]. Several Annexin V-based ima-
ging probes or tracers have been developed for the in
vivo detection of apoptosis by radionuclide, optical,
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and magnetic resonance [MR] imaging techniques
[1,3-9].
Most clinical experience has been gained with the
radioactive tracers 99 mTc-Annexin V [10,11] and 99
mTc-6-hydrazinonicotinic [HYNIC]-radiolabeled
Annexin V, the latter being used in phase II/III trials for
determining the efficacy of chemotherapy in cancer
patients [1]. In animal studies, Cy5.5-labeled Annexin V
is often used for optical apoptosis imaging, including
the monitoring of antitumorigenic therapies [12-14].
Although annexin-based apoptosis imaging has been
applied for assessing the effects of chemo- or radiother-
apy, it has not been applied to the best of our knowl-
edge for monitoring antiangiogenic therapy effects.
Therefore, we investigated near infrared [NIR]-apoptosis
imaging and the uptake of 99 mTc-HYNIC-Annexin V
for assessing antiangiogenic therapy effects in subcuta-
neous A431 xenografts. SU11248 was used as antiangio-
genic drug, a multi-targeted receptor tyrosine kinase
inhibitor that blocks the vascular endothelial growth fac-
tor receptors, the platelet-derived growth factor recep-
tors, and additional receptor tyrsosine kinases. A431 is a
squamous cell carcinoma model [SCC] which responds
very sensitively towards SU11248 [15,16]. We demon-
strate that the in vivo assessment of therapy response in
cancer by apoptosis imaging can be misleading, depend-
ing on the effect of the therapy on tumor
vascularization.
Methods
Tumor inoculation and antiangiogenic therapy
Human epidermoid carcinoma xenografts were induced
by a subscutaneous injection of 4 × 106 A431 cells
(ATTC) in the right hind limb of female nude mice as
described [15,17]. After 10 days of tumor growth, the
animals were divided randomly into a control group (n
= 7 for study I; n = 5 for study II) and a therapy group
(n = 6 for study I; n = 6 for study II). Antiangiogenic
treatment was performed by daily i.p. injection of 50
mg/kg body weight of SU11248 (Pfizer, Inc., New York
City, NY, USA; dissolved in 60 μl DMSO and 30 μl
PBS) for 4 days. Untreated animals were used as con-
trols since application of equimolar concentrations of
the respective solvents had no effects on tumor growth
as described [15].
Study design and imaging protocols
In a first study, we assessed apoptosis in vivo using the
near infrared fluorescence [NIRF] probe Annexin Vivo.
In parallel, the tumor vascularization was analyzed by
NIRF imaging using AngioSense as blood pool contrast
agent and by contrast-enhanced ultrasound.
In a second study, apoptosis was investigated by ex
vivo gamma counting of tumors using the radioactive
tracer 99 mTc-HYNIC-Annexin V. In parallel, tumor
vascularization was assessed in vivo using contrast-
enhanced ultrasound. Imaging and radioactive mea-
surements were performed at day 4 of therapy. This
treatment period results in a significant breakdown of
tumor vessels in A431 tumors as previously observed
[18,19]. The following examination protocols were
applied.
Ultrasound
The tumor volume was determined by non-contrast-
enhanced ultrasound with a small animal ultrasound
system at 25 MHz (Vevo770, RMV710B-transducer;
VisualSonics, Toronto, Canada) by surface rendering.
For assessing the vascularization, contrast-enhanced
ultrasound was performed at the above mentioned scan-
ning system as described [18]. Animals were anesthe-
tized with 1.5% isoflurane. A concentration of 1 × 108 of
self-made polybutylcyanoacrylate microbubbles in 50 μl
were intravenously injected as described [18]. Imaging
(10 frames per second, 16% power) was performed dur-
ing the injection of the microbubbles, and cine loops of
approximately 20 s length were stored for consecutive
analysis. Post-processing of the cine loops was per-
formed by the 2D maximal-intensity-over-time techni-
que as described [18].
Fluorescence molecular tomography
Fluorescence molecular tomography [FMT] was
performed using a wave-type specific scanner for transil-
lumination, reflectance, and absorption as described [20]
(FMT 2500; PerkinElmer Inc., Waltham, MA, USA).
Each mouse received intravenously 2 nmol of Annexin
Vivo 750 (PerkinElmer Inc., Waltham, MA, USA) 2 h
prior to imaging and 2 nmol of AngioSense 680 (Perki-
nElmer Inc., Waltham, MA, USA) immediately before
imaging. Annexin Vivo 750 is a NIR probe that selec-
tively binds phosphatidylserine exposed in the outer
leaflet of the cell membrane during the early stages of
apoptosis. AngioSense 680 is a NIRF agent that remains
localized in the vasculature for 0 to 4 h. In order to
guaranty the assessment of an intravascular probe, FMT
measurements were performed directly after the injec-
tion of AngioSense. This allowed a better comparison
with contrast-enhanced ultrasound where microbubbles
serve as a purely intravascular contrast agent (due to
their size). The mice were anesthetized with isoflurane
during imaging and fixed at a definite position in a two-
modality animal bed (CT Imaging GmbH, Erlangen,
Germany). Quantitative 3D tomography data (in pico-
moles) as well as fluorescence intensities [FI] of 2D
reflectance images were acquired. For 2D reflectance
data, the FI in a similar region of interest [ROI] in the
hind limb muscle on the contralateral side was sub-
tracted from the FI of the tumor in order to reduce the
background signal.
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Computed tomography
For aiding in tumor localization and ROI placement, a
micro computed tomography [CT] scan was performed
directly after the FMT measurement using the dual
energy system Tomoscope Duo CT (CT Imaging
GmbH, Erlangen, Germany). The mice were kept
anesthetized and fixed in the animal bed as for FMT.
The following scan protocol was used: Both tubes ran at
energies of 65 kV. Each flat panel detector acquired 720
projections at 25 frames per second. A full rotation was
performed with a total scan time of 29 s. A Feldkamp
algorithm was used for image reconstruction with an
isotropic voxel size of 70 μm and a sharp reconstruction
kernel (T60). After a total time of a maximum of 10
min for the FMT and CT measurements, the mice were
sacrificed and the tumors were resected.
Quantitative uptake of 99 mTc-HYNIC-Annexin V in tumors
and muscle
For assessing apoptosis by a radioactive probe, we
employed the tracer 99 mTc-HYNIC-Annexin V as
described [3]. The preparation of 99 mTc-HYNIC-
Annexin V was adapted to that of Blankenberg et al. [3].
In brief, 200 μl of 99 mTcO4 was mixed with 150 μl of
HYNIC-Annexin V-tricine solution (41 μg HYNIC-
Annexin V, 115 mM tricine). After dilution with 130 μl
saline, 20 μl stannous chloride (1 mg/ml in 0.05 M HCl)
was added, and the reaction mixture was incubated for
15 min at room temperature. The radiochemical purity
was determined by instant thin layer chromatography.
Ten to fifteen megabecquerel of 99 mTc-HYNIC-
Annexin V (0.0575 nmol) was injected intravenously
into each mouse 2 h prior to sacrifice. For quantitative
determination of the tracer uptake, tumor, liver, and
muscle tissues were resected and measured ex vivo by
gamma counting (Wizard2; PerkinElmer Inc., Waltham,
MA, USA). The number of counts measured in the
tumor, liver, and muscle tissues was corrected for the
injected dose per animal and the radioactive decay (t1/2
(99 mTc) = 6.01 h). The tracer uptake was expressed as
tumor-to-muscle ratio normalized to tissue weight.
Indirect immunofluorescence
For validation, resected tumors were frozen in liquid
nitrogen vapor and cut in 8- to 10-μm slices. Fixation of
the frozen sections and the staining procedure were per-
formed as described [21]. Primary antibodies against
CD31 (rat anti-mouse PECAM-1; BD Biosciences, Hei-
delberg, Germany) for endothelial cell staining, alpha
smooth muscle actin [SMA] (biotinylated mouse anti-
SMA; Progen Biotechnik GmbH, Heidelberg, Germany)
for staining of mature vessels, and collagen IV (rabbit
anti-collagen IV; Novotec, Saint Martin La Garenne,
France) for vessel staining, as well as corresponding sec-
ondary antibodies were used [21]. Cell nuclei were
counterstained by 4’,6-diamidino-2-phenylindole [DAPI]
(Invitrogen, Carlsbad, CA, USA). Apoptotic cells in the
tissue were detected by terminal deoxynucleotidyl trans-
ferase-mediated dUTP nick end labeling [TUNEL] stain-
ing using the ‘In Situ Cell Death Detection Kit, TMR
red’ (Roche Diagnostics GmbH, Mannheim, Germany).
Stained sections were examined and photographed with
the Zeiss Axio Imager M2 (Carl Zeiss MicroImaging
GmbH, Köln, Germany).
Morphometric analysis
Blood vessel density in s.c. tumors was quantified by
determining the ratio of the CD31-stained area to the
total tumor area within the respective field of view. Four
sections at ×10 magnification were analyzed for covering
the whole tumor area. The apoptotic cell rate was deter-
mined by dividing the TUNEL-positive area by the total
DAPI-stained area of the tumor region (stated in
percent).
Statistics
A two-tailed Student’s t test was applied for data analy-
sis using GraphPadPrism 5.0 (Graph-Pad, San Diego,
CA, USA). P < 0.05 was considered as statistically signif-
icant (*) and P < 0.001 as highly significant (**).
Results
In vivo optical apoptosis imaging after antiangiogenic
therapy
Since the benefits of cancer therapies can be attributed
to the induction of apoptosis and necrosis in the tumor
tissue [1], noninvasive apoptosis imaging is of great clin-
ical interest for controlling therapy effects. Therefore,
we analyzed in a first study the accuracy of apoptosis
imaging by FMT using Annexin Vivo after a short-term
treatment of SCC xenografts with SU11248 (4 days). At
this early stage of therapy, the tumor volume was only
slightly smaller in treated tumors compared with
untreated controls (therapy, 28.4 mm3 ± 10.6; control,
36.5 mm3 ± 15.2), as determined by US. Surprisingly,
reconstructed 3D images showed a stronger signal of
Annexin Vivo in control tumors than in treated ones
(Figure 1A, B). Quantification of the 3D data (control
group, n = 7; therapy group, n = 6; Figure 2A) revealed
81.3 ± 73.7 pmol Annexin Vivo/cm3 in control tumors
and 27.5 ± 34.7 pmol/cm3 in treated ones (P = 0.13).
The average 2D FI per area was also slightly higher in
tumors of the control group (Figure 2B; control, 13 ± 15
FI/cm2; therapy, 11 ± 7 FI/cm2; P = 0.79). The in vivo
data were in clear contrast to immunohistology. A
strongly enhanced number of TUNEL-positive apoptotic
cells were detected on sections of treated tumors.
Apoptotic cells were predominantly located in the
tumor center, where only very few vessels were remain-
ing (Figure 2C). Quantification of the TUNEL-positive
area fraction demonstrated a significantly higher
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apoptotic cell rate in the treated group (Figure 2D;
TUNEL-positive area: control, 0.011 ± 0.014%; therapy,
0.461 ± 0.194%; **P < 0.001).
Assessment of tumor vascularization after antiangiogenic
therapy
The low accumulation of Annexin Vivo in the treated
tumors despite their high apoptotic rate suggested either
problems in biodistribution or limitations in probe
delivery to the target tissue. Since the probe is distribu-
ted via the blood circulation and antiangiogenic therapy
affects the tumor vasculature, we assessed the degree of
vascularization in treated and untreated tumors. Tumor
vascularization was analyzed in vivo with FMT using
AngioSense as a blood pool marker and with contrast-
enhanced ultrasound.
Higher AngioSense signals were detected by 3D opti-
cal imaging in the untreated control tumors (Figure 3A,
B), and a higher mean AngioSense concentration was
measured in the controls (Figure 4A; AngioSense/
volume: control group, 13.8 ± 26.2 pmol/cm3; therapy
group, 6.3 ± 7.3 pmol/cm3; P = 0.51). 2D reflection ima-
ging even showed stronger differences in fluorescence
intensity between the controls and treated tumors
(Figure 4B; control group, 38 ± 37 FI/cm2; therapy
group, 15 ± 17 FI/cm2; P = 0.19).
Contrast-enhanced ultrasound confirmed a significant
decrease in tumor vascularization in treated tumors
compared with untreated controls (Figure 4C; control,
285.3 ± 107.5 arbitrary units [a.u.]/mm2; therapy, 87.3 ±
23.9 a.u./mm2; *P < 0.01). The decreased vascularization
in treated tumors was further validated by immunostain-
ing of corresponding tumor sections and subsequent
quantification of CD31-positive area fractions (control
group, 4.8 ± 0.50%; therapy group, 1.7 ± 0.37%; **P <
0.001; Figure 4D; representative pictures are shown in
Figure 4E). The restricted presence of SMA-positive ves-
sels further indicated that in this model, the tumor vas-
culature is predominantly immature and therefore
highly vulnerable to an antiangiogenic therapy (Figure
4E). In the treated tumors, SMA-positive, mature vessels
were only detected at the tumor periphery (Figure 4E).
Uptake of the radiotracer 99 mTc-HYNIC-Annexin V in
response to antiangiogenic treatment and analysis of
vascularization
In order to test whether the low accumulation of the
NIRF-Annexin V probe in the treated tumors was due
Figure 1 Lower Annexin Vivo accumulation in SU11248-treated SCC xenografts. 3D-FMT images showing the Annexin Vivo concentrations
in A431 tumors of representative (A) control and (B) therapy animals. Tumors are marked with arrows; the color-bar represents the
concentrations of the probe in nM.
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to the specificity problems of the probe or due to a
reduced delivery at the target site (as a consequence of
the therapy-induced vascular breakdown), a second ther-
apy study was performed applying a similar therapy
design. Instead of performing NIRF imaging, apoptosis
was now quantified by radioactive measurements using
the radiotracer 99 mTc-HYNIC-Annexin V. Tumor vas-
cularization was again determined in parallel by con-
trast-enhanced ultrasound. Two hours after application
of the radiotracer 99 mTc-HYNIC-Annexin V, the
amount of radioactivity was measured ex vivo in the
tumor, muscle, and liver by gamma counting. Interest-
ingly, the tracer accumulation was similar in the tumors
of the control group compared with the treated group,
as shown by the almost equal tumor-to-muscle ratio
normalized to the tissue weight (Figure 5A; control, 5.66
± 1.46; therapy, 6.09 ± 1.40; P = 0.63). In contrast,
immunohistology demonstrated again a significantly
Figure 2 Low Annexin Vivo accumulation contradicts the high apoptotic rate in corresponding tumor sections. (A) 3D data analysis
reveals a higher mean concentration of Annexin Vivo in the untreated control tumors (control, n = 7; therapy, n = 6), P = 0.13. (B) 2D reflection
data confirm slightly higher mean signal intensity in the control group (same animal number per group), P = 0.79. (C) TUNEL staining of
corresponding tumor sections demonstrates a higher number of apoptotic cells in the SU11248-treated tumors, TUNEL-positive cells in red,
counterstaining of vessels by collagen IV (green), and nuclei stained by DAPI (blue), bar = 100 μm; (D) Quantification confirms a significantly
higher ratio of the TUNEL-positive area fraction in treated tumors, **P < 0.001.
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higher apoptosis rate in the treated tumors (Figure 5B;
TUNEL-positive area: control, 0.023 ± 0.015%; therapy,
0.387 ± 0.105%; *P < 0.001).
In agreement with the first study, contrast-enhanced
ultrasound revealed a significant decrease in the tumor
vascularization in treated tumors compared with
untreated controls (Figure 5C; control, 244.9 ± 58.4 a.u./
mm2; therapy, 127 ± 50.1 a.u./mm2; *P < 0.01). This was
in line with immunohistology, demonstrating a highly
significant decrease in mean blood vessel density in
tumors of the therapy group (Figure 5D; CD31-positive
area: control group, 3.35 ± 0.112%; therapy group, 0.99
± 0.324%; **P < 0.001).
Discussion
Apoptosis imaging is discussed to have an important
potential in the clinics for early disease detection, sta-
ging of disease progression, and the assessment of ther-
apy effects [22]. In cardiovascular medicine, apoptosis
imaging can improve the characterization of myocardial
infarction, instable atherosclerotic plaques, and cardiac
allograft rejection [10,23]. In addition, cancer therapies
strongly induce apoptosis in the tumor tissue already at
an early treatment stage and thus may be monitored
effectively using apoptosis-specific molecular imaging
probes [24]. 99 mTc-Annexin V and 99 mTc-HYNIC-
Annexin V have shown to be promising tracers for
assessing early effects of chemotherapy and radiation
therapy in cancer patients [1,11,25].
In contrast to these findings, we report here that non-
invasive apoptosis imaging as a sole technology is criti-
cal for therapy response evaluation, particularly when
the therapy primarily affects the vasculature. This is pre-
dominantly the case for antiangiogenic therapies.
Already, short-term treatment of SCC xenografts with
the multi-tyrosine kinase inhibitor SU11248 for 4 days
resulted in a strongly reduced vascularization of the
tumor tissue, as indicated by optical imaging and clearly
demonstrated by contrast-enhanced ultrasound and
imunohistology. This observation is in line with previous
studies about the effect of SU11248 on A431 tumor ves-
sels [15,18]. In addition, immunohistology revealed
strong pro-apoptotic effects of the antiangiogenic ther-
apy on the tumor cells, especially within the almost
devascularized center of the tumor, distant from mature
and more functional blood vessels of the tumor periph-
ery [15]. Contradictory to immunohistology, 2D optical
reflection imaging and especially 3D fluorescence tomo-
graphy showed strikingly lower concentrations of the
NIRF probe Annexin Vivo in the treated tumors. These
Figure 3 Higher accumulation of AngioSense in untreated control tumors. 3D-FMT images showing the AngioSense concentrations in
tumors of representative (A) control and (B) therapy animals. Tumors are marked with arrows; the color-bar represents the concentrations of the
probe in nM.
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results pointed either to problems in probe delivery. On
the other hand, since the data for both NIRF probes,
Annexin Vivo and AngioSense, showed high standard
deviations, we could not exclude problems in biodistri-
bution. We therefore performed a second therapy study
with a similar therapy design. Instead of performing
NIRF annexin imaging, we used radiolabeled annexin (99
mTc-HYNIC-Annexin V) and quantitatively determined
the tracer uptake in the tumor by gamma counting.
Almost equal tumor-to-muscle ratios normalized to
Figure 4 Reduction in tumor vascularization after therapy. (A) 3D data analysis reveals a higher mean concentration of AngioSense in the
untreated controls (control, n = 7; therapy, n = 6), P = 0.51. (B) 2D reflection data show an even stronger difference in fluorescence intensities
between control and treated tumors, P = 0.19. (C) Contrast-enhanced ultrasound shows a significantly higher acoustic intensity per tumor area in
control versus treated tumors (*P < 0.01). (D) Quantification of the mean vessel density demonstrates a significantly higher vessel density in the
control group, **P < 0.001. (E) Immunostaining of corresponding sections confirms the markedly increased vessel number in the controls;
endothelial cells are stained with CD31 (green), smooth muscle cells with SMA (red), and cell nuclei with DAPI (blue), bar = 100 μm.
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tissue weight were obtained in therapy and control
tumors, whereas immunohistology again demonstrated a
highly significant increase in apoptosis in the treated
tumors. This demonstrated that also nuclear medicine
measurement of apoptosis using radiolabeled annexin
failed in detecting increased apoptosis after antiangio-
genic therapy. In agreement with the first study, con-
trast-enhanced ultrasound and immunohistology
revealed a significantly reduced vascularization in
SU11248-treated tumors. Thus, we conclude that the
breakdown of the vasculature in response to the antian-
giogenic treatment strongly impairs the delivery of the
probe to the tumor tissue, consequently resulting in a
low probe accumulation despite the enhanced apoptosis.
This hypothesis is supported by the fact that the apop-
totic tumor cells are predominantly located in the center
with only a few remaining vessels and are distant from
SMA-positive, mature blood vessels at the tumor per-
iphery. The remaining functionality of SMA-positive,
mature blood vessels in A431 tumors has been pre-
viously demonstrated by detecting blood flow within the
mature vessels even after antiangiogenic treatment [15].
A431 tumors generally have a low amount of mature
vessels as shown for the untreated controls, demonstrat-
ing the high vulnerability of the vasculature towards the
antiangiogenic therapy. In treated tumors, the number
of mature vessels was even lower than in the controls.
Our conclusion of the problems in probe delivery due
to antiangiogenic therapy is further supported by
dynamic contrast-enhanced MRI of treated mouse colon
xenografts, showing a reduced vascular permeability and
vessel density as early as 24 h after antiangiogenic
Figure 5 99 mTc-HYNIC-Annexin V also fails in detecting enhanced apoptosis when vasculature has regressed. (A) Nuclear measurements
using the tracer 99 mTc-HYNIC-Annexin V reveal almost equal tumor-to-muscle ratios normalized to tissue weight in control and therapy tumors
(control, n = 5; therapy, n = 6), P = 0.63. (B) In contrast to nuclear measurements, quantification of the TUNEL-positive area fraction in sections of
treated tumors demonstrates a highly significant increase in apoptosis in the treated tumors, **P < 0.001. (C) Contrast-enhanced ultrasound
demonstrates again a significantly higher acoustic intensity per tumor area in control versus treated tumors (*P < 0.01). (D) Quantification of the
mean vessel density in tumor sections demonstrates a highly significant decrease in vessel density in the therapy group, **P < 0.001.
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treatment [26,27]. Accumulation of probes or tracers in
tissues with strongly reduced vascularization might be
improved by using smaller molecules like short peptides
instead of proteins since they would more easily pene-
trate and more easily be distributed in the tissue.
Thus, these results favor the use of annexin-based
apoptotis imaging only for cancer therapies that have
minor effects on the tumor vasculature like conventional
chemotherapy or radiation. In addition, apoptosis ima-
ging may be well suited for monitoring cell damage in
disorders where the microvasculature is still present (e.
g., reperfused ischemic areas post infarction or athero-
sclerotic vessels). However, for monitoring cancer ther-
apy effects, our results recommend that apoptosis
imaging should be supplemented by the analysis of
tumor vascularization.
Conclusions
The failure of annexin-based apoptosis assessment in
vivo can be explained by the significant breakdown of
the vasculature after therapy, resulting in reduced deliv-
ery of the probe or the tracer to the target tissue. Thus,
annexin-based apoptosis imaging is only favorable for
therapies that do not severely affect the vasculature.
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